Sunitinib 25mg

Indications for use of Sunitinib 25mg:

According to the BNF (British National Formulary, 60 edition), the drug should be taken in case of resistance or intolerance to the chemotherapy, untreated locally advanced and/or metastatic clear cell renal cell cancer (renal cell carcinoma), or if cytokine therapy proved ineffective.

Way of use and dosage of Sunitinib 25mg:

The effectiveness of treatment is evaluated using the performance indicators: period to the progress of tumor, increase of survival rate and degree of objective answer. According to the BNF ,the recommended dose for the treatment of metastatic clear cell renal cell cancer is 25 mg (orally) every day for 4 consecutive weeks. Then you should take a 2-week break (“4/2” treatment scheme); the full treatment cycle is 6 weeks. The dose should be corrected considering the individual tolerance and safety of use; if necessary, it should be gradually (by 12.5 mg at a time) increased from 25 mg to the maximum of 87.5mg).

Side effects:

pulmonary embolism, thrombocytopenia, tumor bleeding; fatigue; diarrhea, sickness, stomatitis, dyspepsia, vomiting, change in the skin color; dysgeusia and anorexia, yellow skin, decrease in the ejection fraction, AH (arterial hypertension) neutropenia, anemia, thrombocytopenia, leukopenia, hypothyroidism, increased level of lipase and amylase in the blood serum; epileptic seizures in patients with brain metastases; alopecia, exfoliative dermatitis and periorbital edema.

Contraindications:

hypersensitivity to Sunitinib 25mg or any of its components.
Form of production: capsules (25 mg).

Interaction with the other drugs.

Mixing Sunitinib 25mg with ritonavir, itraconazole, erythromycin, clarithromycin and grapefruit juice can increase the concentration of Sunitinib, while dexamethasone, phenytoin, carbamazepine, rifampicin, Phenobarbital or Hypericum perforatum can reduce it; therefore, you should combine Sunitinib 25mg with other medications. If it’s impossible, reduce the dose of Sunitinib; don’t mix the drug with rifampicin and ketoconazole.

Features of use during pregnancy and lactation.
Pregnant women shouldn’t take the drug until the expected beneficial impact exceeds its toxic effect on the fetus.
Lactation: don’t use the drug during lactation.

Features of use in case of failure of internal organs
Cardiovascular disorders: there are no special recommendations.
Liver dysfunction: in case of minor or moderate liver dysfunction, the dosage correction isn’t required.
Kidney dysfunction: patients with a creatinine level that doesn’t exceed the upper bound more than twice, dosage correction isn’t required.
Respiratory disorders: there are no special recommendations.